SERETIDE Vs FLIXOTIDE In Mild Persistent Asthma (GINAII)
Status:
Completed
Trial end date:
2007-07-31
Target enrollment:
Participant gender:
Summary
An 18 months randomised double-blind study with two parallel arms with start dose of inhaled
SERETIDE 50/100mcg BD or FLIXOTIDE 100mcg BD, Phase I is 6 months where the patient will be
up-titrated until well controlled is achieved, After 6 months the treatment continues without
changes during 9 months = PhaseII. The aim is to investigate and evaluate the assumption that
the combination therapy with SERETIDE controls mild persistent asthma better than inhaled
corticosteroids(FLIXOTIDE) alone.
Phase:
Phase 4
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Fluticasone Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Fluticasone-Salmeterol Drug Combination